Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

A Phase 4, Randomized, Double-blind Trial to Evaluate the Immunogenicity and Safety of a 13-valent Pneumococcal Conjugate Vaccine When Administered Concomitantly With Seasonal Inactivated Influenza Vaccine in Adults 50 Years and Older Who Received 1 Or More Doses of 23-valent Pneumococcal Polysaccharide Vaccine Prior to Study Enrollment.

Next Previous
Trial Profile

A Phase 4, Randomized, Double-blind Trial to Evaluate the Immunogenicity and Safety of a 13-valent Pneumococcal Conjugate Vaccine When Administered Concomitantly With Seasonal Inactivated Influenza Vaccine in Adults 50 Years and Older Who Received 1 Or More Doses of 23-valent Pneumococcal Polysaccharide Vaccine Prior to Study Enrollment.

Status: Completed
Phase of Trial: Phase IV

Latest Information Update: 06 Nov 2021

Price : $35 *
  • Adis is an information provider.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
  • A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

  • Drugs Pneumococcal 13-valent CRM197 vaccine conjugate (Primary) ; Influenza virus vaccine
  • Indications Influenza virus infections; Pneumococcal infections
  • Focus Adverse reactions; Pharmacodynamics
  • Sponsors Pfizer

    • Most Recent Events

    • 23 May 2016 Primary endpoints and their time frame (for AE it changed from 6 months to 28-42 days) revised.
    • 05 Jun 2015 Status changed from active, no longer recruiting to completed, as reported by ClinicalTrials.gov record.
    • 03 Feb 2015 Planned End Date changed from 1 Sep 2015 to 1 May 2015, according to ClinicalTrials.gov record.
Subscriber content

You need to be a logged in subscriber to view this content.

If your organization has a subscription then there are several options available to help you access AdisInsight, even while working remotely.

  • IP authentication when working within your organization’s network.
  • with username/password or try via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days.
  • Contact us at AsktheExpert.AdisInsight@springer.com for assistance.

If your organization does not have a subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Buy a PDF version of the profile.
  • Request a free trial
Legal
Back to top